title: Improved regeneration of autologous transplanted lymph node fragments by VEGF-C treatment.
abstract: Secondary lymphedema is a common complication after removal of lymph nodes in combination with radiation therapy in the treatment of breast cancer, cervical cancer, and melanomas. Only symptomatic therapies are available at the moment, and lymphedema is for most patients a lifelong condition involving psychological and physical disabilities. Animal models exist to study the pathophysiology of lymphedema but not to study surgical treatments. The aim of this study was to show that regeneration of autologous transplanted lymph node fragments is possible in rats that were irradiated previously locally in the groin and to examine the effects of vascular endothelial growth factor (VEGF)-C injections on the rate of regeneration of transplanted lymph nodes. In all of the animals, inguinal and popliteal lymph nodes and adjacent lymphatic vessels were unilaterally removed and the inguinal region irradiated by a single dose of 15 Gy. Afterward, lymph node fragments were transplanted subcutaneously in the irradiated region. Half of the animals were treated by local VEGF-C injections after transplantation. Four weeks after transplantation, drainage of the leg was tested by injection of blue dye, and the transplanted fragments were removed and examined immunohistologically. We could show that regeneration of autologous transplanted lymph node fragments is possible in areas treated with radiotherapy in the rat. We also documented that transplants can achieve a connection to the lymphatic collectors of the leg. The results suggest that the outcome of regeneration can be improved by injection of VEGF-C in the transplantation area. Thus, lymph node fragment regeneration may be relevant for lymphedema prevention and therapy.
authors.affiliation: Institute of Immunomorphology, Hannover Medical School, Hannover, Germany.
authors.forename: Tanja
authors.initials: T
authors.lastname: Sommer
authors.forename: Manuela
authors.initials: M
authors.lastname: Buettner
authors.forename: Frank
authors.initials: F
authors.lastname: Bruns
authors.forename: Gerhard
authors.initials: G
authors.lastname: Breves
authors.forename: Catarina
authors.initials: C
authors.lastname: Hadamitzky
authors.forename: Reinhard
authors.initials: R
authors.lastname: Pabst
mesh_terms: D000818:Animals; D005260:Female; D007279:Injections, Subcutaneous; D008197:Lymph Node Excision / Q000009:adverse effects*; D008198:Lymph Nodes / Q000187:drug effects* / Q000503:physiopathology / Q000637:transplantation*; D042583:Lymphangiogenesis / Q000187:drug effects; D008209:Lymphedema / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D051381:Rats; D011917:Rats, Inbred Lew; D012038:Regeneration / Q000187:drug effects*; D013997:Time Factors; D014182:Transplantation, Autologous; D042582:Vascular Endothelial Growth Factor C / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D042582:Vascular Endothelial Growth Factor C